GAITHERSBURG, Md. – Paclitaxel devices used to treat peripheral artery disease (PAD) do show a signal for excess mortality beyond 1 year compared to control devices or treatments, and patients should be made aware of the risks and benefits, an advisory panel to the Food and Drug Administration concluded.